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Some recent studies suggest that in progressive multiple sclerosis, neurodegeneration may occur independently from inﬂamma-
tion. The aim of our study was to analyse the interdependence of inﬂammation, neurodegeneration and disease progression in
various multiple sclerosis stages in relation to lesional activity and clinical course, with a particular focus on progressive
multiple sclerosis. The study is based on detailed quantiﬁcation of different inﬂammatory cells in relation to axonal injury in
67 multiple sclerosis autopsies from different disease stages and 28 controls without neurological disease or brain lesions.
We found that pronounced inﬂammation in the brain is not only present in acute and relapsing multiple sclerosis but also in the
secondary and primary progressive disease. T- and B-cell inﬁltrates correlated with the activity of demyelinating lesions, while
plasma cell inﬁltrates were most pronounced in patients with secondary progressive multiple sclerosis (SPMS) and primary
progressive multiple sclerosis (PPMS) and even persisted, when T- and B-cell inﬁltrates declined to levels seen in age matched
controls. A highly signiﬁcant association between inﬂammation and axonal injury was seen in the global multiple sclerosis
population as well as in progressive multiple sclerosis alone. In older patients (median 76 years) with long-disease duration
(median 372 months), inﬂammatory inﬁltrates declined to levels similar to those found in age-matched controls and the extent
of axonal injury, too, was comparable with that in age-matched controls. Ongoing neurodegeneration in these patients, which
exceeded the extent found in normal controls, could be attributed to confounding pathologies such as Alzheimer’s or vascular
disease. Our study suggests a close association between inﬂammation and neurodegeneration in all lesions and disease stages
of multiple sclerosis. It further indicates that the disease processes of multiple sclerosis may die out in aged patients with
long-standing disease.
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Introduction
Multiple sclerosis is traditionally seen as an inﬂammatory demye-
linating disease of the central nervous system (Charcot, 1880).
It was noticed in the earliest studies on multiple sclerosis pathology
(Kornek and Lassmann, 1999) that axonal injury and loss occur in
the disease lesions; that the extent of axonal injury correlates
with the degree of inﬂammation (Doinikow, 1915; Ferguson
et al., 1997; Kuhlmann et al., 2002; Trapp et al., 1998) and
that axonal loss is a major correlate of permanent disability
(Charcot, 1880; Bjartmar et al., 2000). The traditional view that
inﬂammation is the cause of axonal and neuronal degeneration
in multiple sclerosis brain has recently been challenged. Most
importantly, current anti-inﬂammatory or immunomodulatory
treatments, while partially effective in the relapsing stage of the
disease, have only modest or no effect on the development of
neurodegeneration and clinical disability in the progressive disease
phase and particularly in patients with primary progressive disease
(Coles et al., 1999; Filippi et al., 2000, 2004; Molyneux et al.,
2000). Magnetic resonance imaging and spectroscopy studies
show a very modest correlation between inﬂammation, depicted
by Gd-enhancement (a marker of inﬂammation), and progressive
brain and spinal cord atrophy (markers for neurodegeneration)
(Bielekova et al., 2005; Filippi and Rocca, 2005; Anderson et al.,
2006; Zivadinov and Cox, 2007). Neuropathology reveals
profound axonal loss in the normal appearing white matter
(NAWM), which seems to develop independently from axonal
injury in demyelinated lesions (Lovas et al., 2000; Evangelou
et al., 2005; DeLuca et al., 2006). Furthermore, axonal injury is
also seen in inactive plaques in multiple sclerosis patients (Kornek
et al., 2000), suggesting that chronic demyelination may render
axons particularly vulnerable to progressive injury and destruction.
Finally, ongoing myelin destruction, associated with axonal and
neuronal degeneration, is seen in the cerebral cortex of chronic
multiple sclerosis patients in the absence of parenchymal inﬂam-
matory inﬁltration by T- or B-lymphocytes (Peterson et al., 2001;
Bo et al., 2003). Based on these observations, it has been
suggested that neurodegeneration in multiple sclerosis may occur
independently of inﬂammation or may even be the primary cause
of CNS damage in this disease (Trapp and Nave, 2008). The above
mentioned studies do not exclude the possibility that a diffuse
inﬂammatory process in inactive lesions, the NAWM, the cortex
or the meninges may ultimately drive neurodegeneration at these
sites (Kornek et al., 2000; Kutzelnigg et al., 2005; Magliozzi et al.,
2007). In addition, if demyelination and neurodegeneration in
multiple sclerosis progress independently from inﬂammation,
neurodegeneration should be seen in lesions and NAWM
even when inﬂammation is absent. So far, no systematic
study has correlated axonal injury and destruction in multiple
sclerosis tissue, including the NAWM, with inﬂammation. In
particular, it is unknown, whether disease progression and
neurodegeneration may occur in multiple sclerosis in the absence
of inﬂammation.
Patients and Methods
Sample characterization
This study was performed on parafﬁn embedded archival autopsy
material from 67 multiple sclerosis cases and 28 control cases without
neurological disease or brain lesions. The control cohort included
18 normal controls (young and aged controls) and 10 patients, who
died under septic conditions (Table 1). The clinical course was deﬁned
by retrospective chart review according to established criteria, before
and blinded to the pathological analysis (Lublin and Reingold, 1996).
The multiple sclerosis cohort included nine acute cases, who
died within 1 year of disease onset (Table 1) (Marburg, 1906).
Furthermore, ﬁve cases of relapsing/remitting multiple sclerosis
(RRMS), 35 cases of secondary progressive multiple sclerosis (SPMS)
and 13 cases of primary progressive multiple sclerosis (PPMS) were
included. We also evaluated ﬁve cases of benign or asymptomatic
multiple sclerosis. Asymptomatic disease (n=4) was deﬁned when
routine autopsy revealed multiple sclerosis pathology, but the patients
had no clinical disease history at all. Benign multiple sclerosis (n=1)
was deﬁned when, after 10 years of disease, the EDSS value was
below or equal to 3. Cases were grouped into the three main clinical
groups: acute/relapsing, SPMS and PPMS. Among pooled progressive
(SPMS and PPMS) patients, we identiﬁed two distinct pathological
subgroups: pathologically active progressive disease and pathologically
inactive disease: Pathologically active progressive cases had active
lesions or slowly expanding lesions in white matter or cortex. The
categorization of patients with pathologically active and inactive
disease was based on the analysis of an average of 18 lesions per
case. Although, a single actively demyelinating lesion per case was
sufﬁcient to classify a case as pathologically active, such a scenario
was exceptionally rare, seen for instance in cases with benign or
asymptomatic multiple sclerosis. In average, in patients with patholog-
ically active disease 59% of all lesions were either classical active or
slowly expanding (for detailed deﬁnition of lesional activity see below).
Pathologically inactive cases only had inactive lesions in white matter
and cortex. For all cases an accurate clinical work up including
retrospectively evaluated EDSS (expanded disability status scale)
levels was performed (Kurtzke, 1983). Pathologically inactive disease
patients were signiﬁcantly older, showed longer disease duration and
longer duration of the progressive phase compared with the patholog-
ically active progressive multiple sclerosis patients, but they did not
differ in their EDSS scores 6 to 24 months before death (Table 1).
We also evaluated treatments (steroids or other immunosuppressant
drugs) administered during the last month pre-mortem (Table 1).
Neuropathological techniques and
immunohistochemistry
All cases underwent detailed neuropathological examination on multi-
ple tissue blocks (median 7; 1–43 large blocks or routine blocks) from
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Inﬂammation and neurodegeneration in multiple sclerosis Brain 2009: 132; 1175–1189 | 1177various brain regions, dependent upon the number of lesions seen
by macroscopic inspection. In 17/67 multiple sclerosis cases large
hemispheric or double hemispheric sections were additionally available.
For precise classiﬁcation of white matter lesions sections were stained
with haematoxylin–eosin (HE), luxol fast blue myelin stain (LFB),
and by immunohistochemistry for CD68 (cluster of differentiation)
(macrophages), myelin oligodendrocyte glycoprotein (MOG), cyclic
nucleotide phosphodiesterase (CNPase) and proteolipid protein
(PLP; Fig. 1, Table 2). Active lesions were classiﬁed on the basis of
myelin degradation products within macrophages (Bruck et al., 1995;
Kutzelnigg et al., 2005). Active lesions were densely inﬁltrated
by macrophages containing LFB and PLP reactive myelin degradation
products. These lesions included early-active and late-active stages
(Bruck et al., 1995). Among those lesions two different types could
be distinguished: Acute lesions presented with a dense inﬁltration of
macrophages with myelin degradation products throughout the entire
lesion (Fig. 1A and E). Chronically active lesions contained a broad rim
of macrophages with myelin degradation products at the edge and
macrophages with later stages of myelin degradation products in the
lesion centre. Since in a ﬁrst subset analysis of these different types of
Figure 1 Inﬂammation, demyelination and axonal injury in different multiple sclerosis lesions and the normal appearing white matter.
(A, E, I and M) Panels show an active lesion from a patient with acute multiple sclerosis with active demyelination (A), profound
macrophage (E) and T-cell inﬁltration (I) and extensive acute axonal injury (M), visualized with APP. (B, F, J and N): Panels show
a slowly expanding lesion from a patient with pathologically active progressive multiple sclerosis (SPMS), with focal demyelination (B),
a small but dense rim of CD 68 positive macrophages and microglia at the edge (F). Some of them contain early myelin degradation
products. There is T-cell inﬁltration within the lesion (J) and profound acute axonal injury at the lesion’s edge (N and insert). (C, G, K
and O) Panels show an inactive lesion from a patient with pathologically active progressive multiple sclerosis (SPMS; i.e. presence of
active or slowly expanding lesions at other locations). The focal demyelination is sharply demarcated from the surrounding NAWM (C).
Some CD68 positive macrophages or microglia cells (G), mild tissue inﬁltration with T cells (K) and some APP positive axonal proﬁles
(O) are seen within the inactive lesion. (D, H, L and P) Panels show the NAWM from a case with acute multiple sclerosis. There is no
demyelination (D). Some CD68 positive microglia cells (H), few inﬁltrating T cells (L) and no APP positive axons are present (P). (A–D)
Luxol fast blue myelin staining with PAS reaction (A–D  13) (E–H) Immunohistochemistry for CD 68 (E–G  13, H  130) (I–L)
Immunohistochemistry for CD3 (I, K, L  65 and J  130) (M–P): Immunohistochemistry for APP (M  130, N  13, insert  130,
O, P  65).
1178 | Brain 2009: 132; 1175–1189 J. M. Frischer et al.active lesions, no signiﬁcant differences regarding inﬂammation and
axonal injury were seen (see also Kornek et al., 2000), we pooled
all the active lesions (early active, late active, acute and chronically
active lesions) into one group. Different from the group of active
lesions are the slowly expanding lesions. The latter show an inactive
centre, surrounded by a rim of activated microglia with some macro-
phages at the lesion margin (Fig. 1B and F). Only few of these
macrophages or microglia cells contained early LFB reactive myelin
degradation products. Inactive lesions revealed a sharp lesion border
without macrophage inﬁltration or microglia activation (Fig. 1C
and G). NAWM was deﬁned as a region of the white matter, which
was at least 1cm apart from demyelinated plaques (Fig. 1D and H).
Analysing the entire sample of multiple sclerosis tissue, we identiﬁed
1148 lesions, including 378 active lesions, 222 slowly expanding
lesions and 548 inactive lesions. Out of these lesions, we selected a
representative sample for detailed quantitative analysis, depending
upon the presence of different lesion types per case. The aim of the
selection was to include at least two samples of each lesion type, if
present. In patients with inactive lesions only, two samples were taken,
whereas in patients with different lesion types (active lesions, slowly
expanding lesions and inactive lesions) the sample was accordingly
larger. Thus immunocytochemistry and quantitative evaluation was
done on 228 multiple sclerosis lesions (85 active, 50 slowly expanding
and 93 inactive). Further, 139 areas of NAWM, 121 areas of meninges
and 120 areas of cortex were analysed in multiple sclerosis cases.
Cortical lesions were categorized slightly differently than white
matter lesions (Peterson et al., 2001; Dal-Bianco et al., 2008).
Active lesions in the cortex showed a high-density rim of HLA-D
and CD68 positive microglia––macrophages at the lesion margins.
Some of them contained early myelin degradation products. Inactive
cortical plaques were demyelinated lesions without increased numbers
of microglia–macrophages at their borders and without myelin
degradation products in macrophages or microglia. In controls, areas
of normal white matter (n=41), meninges (n=37) and normal cortex
(n=33) were included in the sample (Table 1).
Immunohistochemistry was performed on parafﬁn sections as
described previously (Bauer et al., 2007; King et al., 1997). For a
detailed list of primary antibodies, dilutions and the corresponding
pre-treatment see Table 2.
Quantitative analysis
All sections were digitally scanned and speciﬁc lesions and regions of
interest were manually outlined, and lesional activity was deﬁned as
described above. Each lesion type and randomly sampled areas
of NAWM, meninges and cortex were quantitatively analysed.
Perivascular and parenchymal inﬂammatory cells were counted
separately, but later pooled for statistical analysis. If more lesions
from a given activity stage were found in a selected slide, all lesions
were counted and the values were pooled. This resulted in up to three
distinct lesion types per patient with different stages of activity: active
lesions, slowly expanding lesions and inactive lesions. Additionally,
values per patient were acquired for the NAWM, the meninges
and the cortex. For quantiﬁcation, the immunostained sections were
overlaid by a morphometric grid and inﬂammatory cell numbers or
acutely injured or transected axons were manually counted in 5–100
ﬁelds per tissue area. The number of ﬁelds, selected per lesion and the
applied magniﬁcation depended upon the overall density of cells or
pathological axons and upon their even or uneven distribution within
the tissue. For example, due to their low numbers within the tissue,
Table 2 Antibodies used for immunocytochemistry
Primary antibodies
# Antigen Pre-
treatment
Dilution Antibody
type
Target Source
1 CD3 ST, E 1:1000 CSA Ab; rabbit T-cell receptor LabVision, Freemont, CA, USA
2 CD 20 ST, E 1:100 mAb; mouse B-cell receptor LabVision, Freemont, CA, USA
3 HLA-DR ST, C 1:100 mAb; mouse Human leucocyte antigen, MHC Class
II antigen, microglia, macrophages
DAKO, Glostrup, Denmark
4 Ig P 1:200 Ab; sheep Human immunglobulin––plasma cells Amersham Pharmacia Biotech,
Uppsala, Sweden
5 NF 150kD ST, E 1:2000 Ab; rabbit Phosphorylated neuroﬁlament chain M Chemicon, Temecula, CA, USA
6 APP ST, C 1:1000 mAb; mouse APP; beta/A4 Chemicon, Temecula, CA, USA
7 SPY ST, E 1: 200 Ab; rabbit Synaptic vesicle protein, C term Dako, Glostrup, Denmark
8 SMI 312 ST, E 1: 18000 mAb; mouse Phosphorylated pan-neuroﬁlament Abcam, Cambridge, UK
9 CD4 ST, E 1: 100 mAb; mouse T-helper cells LabVision, Freemont, CA, USA
10 CD8 ST, E 1:250 CSA mAb mouse T-cytotoxic cells Dako, Glostrup, Denmark
11 CD138 ST, E 1:500 mAb; mouse Plasma cells Serotec, Raleigh, USA
12 CD 68 ST, E 1:100 mAb; mouse Sialomucin microglia, macrophages Dako, Glostrup, Denmark
13 PLP ST, E 1:1000 mAb; mouse Proteolipid protein myelin Serotec, Oxford, UK
14 MOG ST, C 1:1000 mAb; mouse Myelin oligodendrocyte glycoprotein Kindly provided by Sara Piddlesden
(Piddlesden et al., 1993)
15 CNPase ST, E 1:2000 mAb; mouse Myelin 2030 cyclic nucleotide 30
phosphodiesterase
Sternberger Monoclonals Inc.,
Lutherville, MD
Table 2 gives an overview of the antibodies used in this study. Antibodies 1–6 were stained and evaluated quantitatively on all multiple sclerosis cases and all controls.
Antibody # 7 was stained and evaluated quantitatively on progressive multiple sclerosis cases and all controls. Antibody # 8 was stained and evaluated quantitatively on
a subset of cases (Fig. 5). Antibodies # 9–11 were applied on a selected sample for validation of our data. Antibodies # 12, 13 were used on all sections available per
case for lesion classiﬁcation. Antibodies # 14, 15 were used on sections with active plaques in order to distinguish between early active and late active plaques.
Ab=polyclonal antibody; C=Citrate buffer (10mM, pH 6.0); CSA=catalysed signal ampliﬁcation; E=EDTA (EDTA 1mM, Tris 10mM), pH 9.0; mAb=monoclonal
antibody; P=0.03% Protease; SPY=synaptophysin; ST=Steamer.
Inﬂammation and neurodegeneration in multiple sclerosis Brain 2009: 132; 1175–1189 | 1179Figure 2 Density of inﬂammatory inﬁltrates and axonal injury in relation to lesional activity and disease course. Graphs display densities
of T cells (A), B cells (B), plasma cells (C), microglia/macrophages (D) as well as APP positive (E) and neuroﬁlament positive axonal
injury (F) in different lesion types, NAWM, meninges and cortex separated for the three main disease courses: acute–relapsing multiple
sclerosis, SPMS and PPMS. Values of normal control white matter, cortex and meninges are additionally shown. The graph depicts the
density of inﬂammatory inﬁltrates and axonal injury in relation to lesional activity and disease course. Inserts show the densities of
inﬂammatory inﬁltrates in inactive lesions and the NAWM in more detail. Box plots represent median value (50th percentile) and range
of lesional densities. Outliers (values that are between 1.5 and 3 times the interquartile range) are marked with a circle. Extreme values
(values that are more than three times the interquartile range) are marked with an asterisk. Values are mean values for each present
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In addition, perivascular accumulation of inﬂammatory cells in perivas-
cular cuffs in active lesions required counting in large numbers of ﬁelds
to obtain reliable values for global cell density. Thus we analysed 5
to 30 ﬁelds per lesion for CD3 and HLA-D (0.3–1.9mm
2); 20–40 ﬁelds
per lesion for amyloid precursor protein (APP) (5–10mm
2), neuroﬁla-
ment-M (1.25–2.5mm
2), synaptophysin (SPY) (1.25–2.5mm
2) and
SMI 312 (1.25–2.5mm
2), whereas 50–100 ﬁelds were counted per
lesion for B cells and plasma cells (3.12–6.25mm
2). In normal controls,
randomly sampled areas of NAWM were quantiﬁed in the same way.
Cortical values were obtained differently: For T cells, B cells, plasma
cells and axonal injury the total area of cortex per slide was quantiﬁed.
Similarly, inﬂammation in the meninges was quantiﬁed over the entire
cortex per slide. The area of meninges was determined using a
morphometric grid as described in detail before (Dal-Bianco et al.,
2008). For HLA-D, the total area of active lesions, inactive lesions
and normal appearing grey matter (NAGM) was measured. Five to
twenty ﬁelds (0.3–1.25mm
2) per lesion and NAGM were quantiﬁed
as described for the white matter. An overall cortical value was
calculated by multiplication of the normalized lesional and NAGM
values with the respective area size in square millimetre. These
values were added and the sum was divided with the total cortical
area per slide.
All values are expressed as cell counts per square millimetre. The
total sample was quantiﬁed for CD3, CD20, Ig and HLA-D positive
cells. In order to verify our own data, we also performed a quantitative
analysis of CD4, CD8 and CD138 positive cells on a subset of cases.
Axonal injury was assessed and quantiﬁed using antibodies directed
against APP, SPY, neuroﬁlament M (Table 2). Quantitative analysis
was carried out for APP, SPY, neuroﬁlament M, and SMI312.
An inter-rater agreement was assessed between three independent
investigators (J.F., S.B. and H. Lassmann) for the quantitative analysis
on a selection of randomly sampled slides and markers.
Statistical analysis
Due to the uneven distribution of our data, statistical analysis was
performed with non-parametric tests. Descriptive analysis included
median value and range. Differences between two groups were
assessed with Wilcoxon–Mann–Whitney U-test. Differences between
more than two groups were assessed with Kruskal–Wallis test,
followed by pairwise Wilcoxon–Mann–Whitney U-tests. In case of
multiple testing (comparison of more than two groups), signiﬁcant
values were corrected with Bonferroni–Holm or Shaffer’s procedure
as appropriate. Interdependence of variables was evaluated by
Spearman non-parametric correlation test. Differences in the incidence
of confounding pathology were assessed by comparison of observed
and expected counts with Fisher’s exact test. SPSS 14.0 statistical
software system (SPSS Inc., Chicago, IL) was used for calculations.
The reported P-values are results of two-sided tests. A P-value smaller
or equal to 0.05 is considered statistically signiﬁcant after Bonferroni–
Holm or Shaffer’s correction for multiple testing. For all statistical
analysis, distinct values per patient for each present lesion type,
NAWM, meninges and cortex were used. If necessary for certain
statistical analysis, lesions were pooled in one group. Differences
between multiple sclerosis patients and controls were ﬁrst assessed
by comparing different types of lesions pooled from all types of this
disease, to normal control NAWM and septic control NAWM. Patient
NAWM was compared to control NAWM. Multiple sclerosis meningeal
and cortical values were equally compared to respective control areas.
Differences between pathologically active progressive and pathologi-
cally inactive disease were ﬁrst assessed by pooling all lesional, normal
white matter, meningeal and cortical values. In order to achieve
a more accurate comparison of pathologically active progressive and
pathologically inactive disease, we also compared those disease
courses separately in lesions of the same stage of activity (lesion
types), in the NAWM, the meninges and the cortex. The interdepen-
dences of inﬂammatory inﬁltrates and axonal injury with age and
disease duration were also analysed separately in pooled lesions,
NAWM and cortex. The interdependence of inﬂammatory inﬁltrates
and axonal injury was analysed separately in pooled lesions, the
NAWM, meninges and cortex.
Results
Inﬂammation reﬂects the activity of
the disease process in demyelinating
lesions and in different disease stages
In a ﬁrst step, we analysed the density of inﬂammatory inﬁltrates
in relation to lesional activity (Fig. 2, Supplementary Table 1).
As expected, the most pronounced inﬂammation by T cells was
seen in active lesions (Figs 2A and 1I), which are most frequent in
patients with acute or RRMS (Table 1). Those were followed
by slowly expanding lesions, which were only found in the
progressive stage of the disease (Figs 2A and 1J). Much lower
numbers of T cells were seen in inactive lesions and in the
lesion type or area per patient. The densities of T-cells and microglia/macrophages are highest in active lesions, followed by slowly
expanding lesions and inactive lesions (A and D). B-cell inﬁltration is mainly seen in active lesions and meninges followed by slowly
expanding lesions (B), while plasma cells are predominantly found in meninges (C). Equally, axonal injury (E and F) is mainly seen in
active lesions and slowly expanding lesions. Active lesions and slowly expanding lesions separated for acute–relapsing, SPMS or PPMS
cases all display signiﬁcantly higher levels compared to normal control WM for all inﬂammatory and neurodegenerative markers (A–F).
Meningeal inﬁltrates of T cells (A), B cells (B) and plasma cells (C) in acute–relapsing, SPMS and PPMS cases equally display signiﬁcantly
higher levels than pooled control meninges. The same situation applies when inﬂammatory inﬁltrates and axonal injury of active lesions
and slowly expanding lesions or meningeal inﬂammatory inﬁltrates, separated for acute–relapsing, SPMS and PPMS, are compared to
pooled control WM (with septic controls). Inactive lesions in acute–relapsing multiple sclerosis cases display signiﬁcantly higher T cell (A)
and B cell (B insert) inﬁltrates and signiﬁcantly more APP positive (E) and NF-M positive (F) axonal injury compared to normal control
white matter. Inactive lesions in PPMS and SPMS cases show a heterogeneous pattern of differences compared to normal or pooled
controls (see Results section and separation of SPMS and PPMS cases into the categories of pathologically active progressive and
pathologically inactive). We do not observe signiﬁcant differences between SPMS and PPMS cases. (F) In order to simplify graphical
presentation three acute–relapsing multiple sclerosis active lesional extreme values have been cut.
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cortical parenchyma, but there was pronounced inﬁltration in
the meninges (Fig. 2A). Consistent with prior studies (Gay et al.,
1997; Babbe et al., 2000), a sub-analysis of CD4 and CD8 positive
T cells revealed that the majority of T-cell inﬁltration in multiple
sclerosis lesions consisted of CD8 positive T cells (data not shown).
A similar pattern of inﬂammation was seen for B cells (Fig. 2B)
and HLA-D-positive macrophages and microglia cells (Fig. 2D). In
comparison to T cells, the number of B cells was on average
10 times lower and these cells were predominantly seen in
perivascular cuffs or meninges and only few of them dispersed
into the parenchyma. HLA-D positive cells revealed a dominant
macrophage phenotype in all active lesions (Fig. 1A and E). In
slowly expanding lesions, most HLA-D positive cells displayed a
microglia phenotype with only few intermingled macrophages.
A ramiﬁed microglia like phenotype dominated in inactive lesions,
cortex and NAWM (Fig. 1G, I and H). Plasma cells (Fig. 2C) were
sparse in the parenchyma of lesions, NAWM and cortex. They
mainly accumulated in the perivascular and meningeal connective
tissue spaces of the brain and revealed only little relation to
lesional activity. As described before by Magliozzi et al., (2007)
lymph follicle-like structures were found in the meninges in 15/67
multiple sclerosis cases. In patients with SPMS and PPMS, such
follicles were only present in cases with active progressive disease
(for deﬁnition see below).
In relation to disease stage, we found most profound inﬂamma-
tion in patients with acute/relapsing disease followed by those
with progressive disease. This was similar for T and B cells. In
contrast, plasma cells were mainly seen in lesions, NAWM and
meninges in patients with progressive disease, but were less
abundant in patients, who died during the acute/relapsing stage.
When individual lesion types (active lesions, slowly expanding
lesions and inactive lesions) were compared no signiﬁcant
differences in the density of inﬂammatory inﬁltrates were noted
between SPMS and PPMS.
Given the archival nature of our tissue resources, the vast
majority of our patients died before modern immunomodulatory
treatments were available. Nevertheless, we analysed the potential
impact of steroid or other immunosuppressive treatment on
our ﬁndings. Comparing those with and those without steroid
treatment, there were no signiﬁcant differences observed in the
extent of inﬂammation in lesions, NAWM, meninges and cortex
when pooling all multiple sclerosis types.
Axonal degeneration in multiple
sclerosis brains
For analysis of acute axonal injury, we used markers of fast axonal
transport, APP and SPY as well as the presence of focal axonal
swellings and end-bulbs (axonal spheroids) that stained for neu-
roﬁlament epitopes. Active multiple sclerosis lesions demonstrated
a high number of acutely injured axons as evidenced by focal
accumulations of APP or SPY. Only a fraction of those axons
with disturbed axonal transport also stained as axonal end-bulbs
positive for neuroﬁlament. In contrast, in inactive lesions, axonal
spheroids, reactive for neuroﬁlament markers, were present, which
did not contain APP or SPY. This suggests that disturbance of
axonal transport (APP––or SPY––positive axons) is likely an initial
but transient phenomenon of acute axonal injury, whereas neuro-
ﬁlament positive axonal spheroids may be retained within lesions
for a more prolonged period of time.
As expected, the most extensive acute axonal injury was seen in
active plaques, followed in the order of magnitude by slowly
expanding lesions, inactive plaques, NAWM and cortex (Fig. 2E
and F). This was similar for APP positive axons (Fig. 2E) and
neuroﬁlament positive axonal end-bulbs (Fig. 2F), although the
absolute numbers of immunoreactive proﬁles were different.
Since classical active lesions were enriched in patients with acute
and relapsing disease, and these lesions showed the highest den-
sity of acutely injured axons; it was not surprising that more acute
axonal injury (APP positive) was seen in these patients compared
with those with progressive disease. However, when we compared
lesions of the same stage of activity, there were no signiﬁcant
differences in the extent of axonal injury between acute–relapsing,
SPMS and PPMS patients. Thus, the density of acutely injured
axonal proﬁles was similar in active or inactive lesions, respectively,
regardless whether they were present in acute/relapsing or pro-
gressive multiple sclerosis. The same applied to NAWM, with one
exception: Neuroﬁlament-M positive axonal spheroids were pres-
ent in a signiﬁcantly higher amount in the NAWM of progressive
disease patients (pooled PPMS and SPMS; P50.05) than in acute–
relapsing disease patients (Fig. 2F). As with inﬂammation no sig-
niﬁcant differences were seen regarding axonal damage, when
individual lesions types (active lesions, slowly expanding lesions
and inactive lesions) or NAWM were compared between SPMS
and PPMS. No differences were seen in the extent of axonal injury
between male and female patients (data not shown).
Axonal injury is associated with
inﬂammation not only in all multiple
sclerosis stages but also in progressive
multiple sclerosis alone
When all lesions included in this study were pooled, we found
a signiﬁcant correlation between the extent of acute axonal
injury with the number of inﬂammatory cells, quantiﬁed in
consecutive sections (T cells: P50.001, r=0.6; B cells: P50.01;
r=0.3; Plasma cells P50.05; r=0.2; HLA-D: P50.001; r=0.7).
Similar results were obtained when the extent of neuroﬁlament
reactive end-bulbs was correlated with inﬂammation (T cells:
P50.001; r=0.5; B cells: P50.01; r=0.3; Plasma cells P50.01;
r=0.3; HLA-D: P50.001, r=0.6).
Since, it has been suggested that in progressive multiple sclerosis
(SPMS and PPMS) axonal injury may develop independently from
inﬂammation we performed similar correlative studies only in
patients with progressive multiple sclerosis, excluding cases with
acute and relapsing disease. Even in this analysis we found very
similar correlations between inﬂammation and axonal damage
(Fig. 3A, Supplementary Table 2). The correlations for APP reac-
tive axonal proﬁles were P50.001, r=0.5 for T cells, P50.05,
r=0.2 for B cells, P50.05, r=0.3 for plasma cells and P50.001,
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ilar signiﬁcance levels and correlation coefﬁcients were seen
when neuroﬁlament reactive end-bulbs were used as a marker
for axonal degeneration. Furthermore, the data were conﬁrmed
by using another marker for acute disturbance of axonal trans-
port (SPY) (Fig. 3B). A correlation between axonal injury and
inﬂammation was not only seen in lesions in the progressive
stage of the disease, but also in the NAWM. There, SPY reactive
axonal proﬁles correlated with the number of T cells (P50.01,
r=0.4) and B cells (P50.01, r=0.5).
These data show that not only in the acute and relapsing stage
of the disease but also in progressive multiple sclerosis (SPMS and
PPMS), axonal injury is associated with inﬂammation. This is dif-
ferent from what we found in control brains: There, acute axonal
injury, depicted by the focal expression of APP, is only associated
with HLA-D positive macrophages and microglia (P50.01; r=0.3),
but not with the numbers of T cells, B cells and plasma cells within
the tissue.
Inﬂammation and axonal injury
declines to levels seen in age-matched
controls in aged multiple sclerosis
patients with pathologically inactive
disease
In patients with PPMS and SPMS, the density of inﬂammatory
inﬁltrates as well as of dystrophic axons in lesions and NAWM
was highly variable between patients. Furthermore, we found
signiﬁcant negative correlations between age (Fig. 3C and D;
Supplementary Table 2) or disease duration and inﬂammatory
Figure 3 (A and B) Graphs show examples of the interdependence of inﬂammation and neurodegeneration among progressive
multiple sclerosis patients (SPMS and PPMS). Multiple sclerosis values represent lesional mean values for all lesion types per patient. We
observe highly signiﬁcant positive correlations between acute axonal injuries and inﬂammatory inﬁltrates (A and B) among progressive
multiple sclerosis patients. We also ﬁnd those correlations when analysed in all multiple sclerosis cases (acute–relapsing, SPMS and
PPMS) (see Results section). (C and D) Graphs express examples of the relation between age and densities of inﬂammatory inﬁltrates
(C) or axonal injury (D) in progressive multiple sclerosis (SPMS and PPMS) lesions. Multiple sclerosis values represent lesional values for
all lesion types per patient. We ﬁnd highly signiﬁcant negative correlations between inﬂammation and age at death (C) and age at
death and axonal injury (D) among progressive multiple sclerosis patients. Those negative correlations also persist when analysed in all
multiple sclerosis patients (see Results section). For more detailed information see Supplementary Table 2.
Inﬂammation and neurodegeneration in multiple sclerosis Brain 2009: 132; 1175–1189 | 1183Figure 4 The graph displays the differences between pathologically active progressive multiple sclerosis, pathologically inactive multiple
sclerosis and controls (normal and septic controls). Among pooled progressive multiple sclerosis (SPMS and PPMS) patients, we have
identiﬁed two distinct pathological subgroups: Pathologically active progressive multiple sclerosis cases had active lesions or slowly
expanding lesions in white matter or cortex. Pathologically inactive multiple sclerosis cases only had inactive lesions in white matter
and cortex. Apart from signiﬁcant differences in their clinical presentation (Table 1), those entities also differ in their pathological
presentation. Overall, pathologically active progressive disease cases display signiﬁcantly higher densities of inﬂammatory inﬁltrates
(A–D) and axonal injury (E and F) than pathologically inactive disease cases. Importantly, these differences remained when analysing
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SPMS and PPMS patients, very low numbers of inﬂammatory cells
and dystrophic axons were seen.
To assess this point we divided the patients, who died in the late
progressive stage (all SPMS and PPMS patients) of the disease
into two categories: Patients with pathologically active progressive
disease, where global neuropathological analysis revealed the
persistence of classical active or slowly expanding lesions, and
patients with pathologically inactive disease, who showed inactive
plaques only. In comparison to those with pathologically active
progressive disease, patients with pathologically inactive disease
were signiﬁcantly older and had signiﬁcantly longer disease
duration, while their extent of clinical deﬁcit at the time of
death was similar (Table 1). The percentages of patients with
pathologically active progressive and pathologically inactive
disease were similar among SPMS and PPMS (Table 1).
In contrast to those with pathologically active progressive
disease, inﬂammatory inﬁltrates of pathologically inactive disease
patients were signiﬁcantly lower and declined to levels seen in age
matched or septic controls (Fig. 4A–D; Supplementary Table 3).
However, among pathologically inactive patients, a modest but
signiﬁcantly higher amount of meningeal plasma cell and B-cell
densities (P50.05) were observed compared with normal controls.
When analysing neurodegeneration in these patients, we found
that they also had signiﬁcantly less acute axonal injury as
compared to those, who died during the pathologically active
progressive phase (Fig. 4E and F). Furthermore, pathologically
inactive patients displayed densities of acutely injured axons or
of neuroﬁlament reactive axonal end-bulbs, similar to those seen
in age-matched controls (Fig. 4E and F). Additionally to the data
shown in Fig. 4, we also assessed the differences between patho-
logically active progressive and inactive disease separately in inac-
tive lesions, the NAWM and meninges (i.e. comparable lesions
types; see Supplementary Table 3). Remarkably, even when
comparing any of these relatively silent lesions or areas, we
found signiﬁcantly higher densities of inﬂammatory inﬁltrates
and axonal injury among pathologically active than inactive
patients (see Supplementary Table 3). These data suggest that
multiple sclerosis-related neurodegeneration ceases in parallel to
the inﬂammatory reaction.
One can argue that such patients do not reﬂect the normal
course of the disease, but represent a selected sample of patients
with benign multiple sclerosis. This is not the case, since neuro-
logical disability (median EDSS 8.5) in these patients was similar to
that seen in patients, who died during the pathologically active
progressive phase of the disease (Table 1). To further address this
issue, we analysed a separate tissue collection from ﬁve patients
with asymptomatic or benign multiple sclerosis. These patients
were either diagnosed at autopsy without preceding clinical
disease or only had a few bouts at the onset of the disease
without further deterioration. In their brains, only few lesions
were seen. In contrast to pathologically inactive disease cases, in
asymptomatic or benign multiple sclerosis, classical active or slowly
expanding lesions were found as well as inactive lesions. Lesions in
these patients displayed a similar extent of inﬂammation and
axonal injury, as did lesions of the same stage of activity in
pathologically active progressive patients (data not shown).
Additional neurodegenerative changes
in pathologically inactive multiple
sclerosis
Three different additional pathologies were encountered in the
brains of patients, who died in the pathologically inactive stage
of multiple sclerosis) (Fig. 8): unusually thick demyelinated axons
within inactive plaques (Fig. 5A), synaptic patterns of SPY
immunoreactivity within lesions and the NAWM (Fig. 5B and C)
and axonal or neuronal injury due to confounding pathology
(Fig. 5D).
As described before (Shintaku et al., 1988; Lovas et al., 2000;
Bergers et al., 2002; Fisher et al., 2007), unusually thick demye-
linated axons with high reactivity for phosphorylated neuro-
ﬁlament (Fig. 5A) were present in variable numbers in all
chronically demyelinated plaques in patients with progressive
disease. These axonal changes may represent a chronic axonal
reaction to demyelination (Waxman, 2008; Young et al., 2008;
Mahad et al., 2009).
In sections stained for SPY, we frequently encountered dense
clusters of small immunoreactive proﬁles, closely similar to SPY
positive synapses in the grey matter. They were mainly located
in periventricular or perivascular areas in chronic demyelinated
plaques with severe axonal loss (Fig. 5B and C), but were also
found in the NAWM. They may represent synaptic sprouts,
originating from transsected axons.
In our multiple sclerosis sample, 16 patients were identiﬁed who
had confounding pathology (Table 1). This was more frequently
seen among aged multiple sclerosis patients with pathologically
inactive disease than among acute–relapsing or pathologically
active progressive multiple sclerosis patients (P50.01). Eleven
patients revealed cortical lesions consisting of amyloid plaques
inactive lesions or NAWM only (see Supplementary Table 3). In addition, pathologically active progressive disease cases also display
signiﬁcantly higher densities of inﬂammatory inﬁltrates (A–D) and axonal injury (E and F) than pooled controls. These differences were
consistent using pooled data or values from either inactive lesions or NAWM only (the latter two not shown). Remarkably, even when
using pooled data, both inﬂammatory inﬁltrates (A, C and D) and axonal injury (E and F) of pathologically inactive disease cases were in
the range of normal or pooled control values. Areas of confounding pathology are not included. Multiple sclerosis values are lesional,
normal appearing white matter, cortical and meningeal densities of inﬂammatory inﬁltrates (A–D) and lesional, NAWM and cortical
densities of axonal injury (E and F). Control values are white matter, cortical and meningeal densities of inﬂammatory inﬁltrates (A–D)
and white matter and cortical densities of axonal injury (E and F). Differences between pathologically active progressive, pathologically
inactive disease and pooled controls have been assessed with Mann–Whitney U-tests by pooling all values (lesional, white matter,
cortical and meningeal values). P-values are corrected with Shaffer’s procedure. AL=active lesions; SEL=slowly expanding lesions;
IAL=inactive lesions; WM, white matter; CO, cortex; ME, meninges; NS=not signiﬁcant; *P50.05; **P50.01; ***P50.001.
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for neuropathological diagnosis of Alzheimer’s disease (Dal-Bianco
et al., 2008). As Alzheimer’s disease was most frequent among
pathologically inactive patients (P50.01), we compared within this
subgroup those with and without Alzheimer’s disease pathology:
In patients with concomitant Alzheimer’s disease pathology, we
found signiﬁcantly more acute axonal injury in the cortex and in
the white matter (P50.05) compared to multiple sclerosis patients
with pathologically inactive disease and the absence of Alzheimer
type pathology (Fig. 5E–G). Acute axonal injury in the white matter
of Alzheimer’s disease patients most likely reﬂects Wallerian degen-
eration due to loss of cortical neurons. In addition, eight patients
showed small focal ischaemic lesions in the white or grey matter.
Not surprisingly, tract degeneration was seen within and around
these vascular lesions (Fig. 5D). These data underline that in
progressive multiple sclerosis patients, neurodegeneration may
progress due to age-related concurrent diseases, even when multi-
ple sclerosis related inﬂammation and axonal injury have ceased.
Discussion
One of the key results of our study is that in the progressive stage
of the disease, active demyelination and neurodegeneration are
Figure 5 Additional CNS pathologies in multiple sclerosis patients with pathologically inactive disease. In the brains of patients with
late stage inactive multiple sclerosis, different additional pathologies are observed: (A) Staining for phosphorylated neuroﬁlament
(SMI312,  140) revealed unusually thick demyelinated axons in inactive plaques. Clusters of synaptophysin reactivity (B and C  70)
are located periventricularly (B) and perivascularly (C) within inactive lesions with severe axonal loss. In a patient with concomitant
vascular pathology, axonal tract degeneration is visualized by APP staining (D  70). Since Alzheimer’s disease was most frequent in
pathologically inactive disease patients, we compared the extent of axonal injury in cortex (E) and NAWM (F and G) of inactive multiple
sclerosis patients (n=12) with and without concomitant Alzheimer’s disease. The graphs express the density of axons positive for APP
(E and F) or phosphorylated neuroﬁlament (SMI312, G). Values represent cortical mean values and NAWM mean values per patient.
Box plots represent median value (50th percentile) and range. Extreme values (values that are more than three times the interquartile
range) are marked with an asterisk. Those patients with concomitant Alzheimer’s disease pathology (n=5) show signiﬁcantly more
cortical neurodegeneration (E) than those without (n=7). In the NAWM patients with concomitant Alzheimer’s disease pathology
show signiﬁcantly more chronic axonal injury (G) but only a trend to more acute axonal injury (F).
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Further, we also show that in aged patients at the late stage of the
disease, the inﬂammatory process may die out and inﬂammation
declines to levels seen in age-matched controls. In this situation,
ongoing neurodegeneration is reduced to the levels seen in
controls, provided there is no confounding age-related disease,
such as Alzheimer’s or vascular disease.
Thus, there is no doubt that the pathology of progressive
multiple sclerosis is fully consistent with that of a classical inﬂam-
matory disease. This contrasts with MRI ﬁndings that show only
rare Gadolinium (Gd)-enhancing lesions in comparable patients,
clearly documenting a dissociation between Gd-enhancement
and progressive damage of the grey and white matter
(Bielekova et al., 2005; Filippi and Rocca, 2005; Anderson et al.,
2006; Zivadinov and Cox, 2007; Waxman, 2008; Young et al.,
2008). Furthermore, the question arises, why anti-inﬂammatory
therapies are largely ineffective in the progressive disease stage
and in particular in patients with PPMS (Coles et al., 1999;
Molyneux et al., 2000). One possible explanation is that in the
progressive stage of multiple sclerosis, inﬂammation becomes
trapped within the brain compartment behind a closed or repaired
blood–brain barrier. In fact, dissociation between inﬂammation
and blood–brain barrier disturbance in multiple sclerosis patients
has been described by using a speciﬁc marker, which selectively
stained leaky endothelial cells in brain vessels (Hochmeister et al.,
2006). Most importantly many vessels with profound perivascular
inﬂammation in the absence of leaky endothelial cells were seen in
patients with progressive multiple sclerosis. Furthermore, in the
progressive stage of multiple sclerosis, lymph follicle-like structures
are formed in the meninges and in the large perivascular spaces.
Those lymph-follicle-like structures are associated with rapid
disease progression and profound brain damage (Magliozzi
et al., 2007). It has been suggested that chronic inﬂammation
within the brains of multiple sclerosis patients creates a microen-
vironment, which favours homing and retention of inﬂammatory
cells within this compartment (Krumbholz et al., 2005; Meinl
et al., 2008).
Another interesting aspect of inﬂammation in multiple sclerosis
is the difference in the pattern of T-cell, B-cell and plasma cell
inﬁltration. T cells, and to a lesser degree B cells are markers for
the activity of the disease process and tissue damage. The more
active lesions are, the more of these cells are seen within the
tissue. However, there are compartmental differences in the
distribution of these cells. T cells are seen in large perivascular
cuffs especially in active lesions in the acute and relapsing disease
stage but they also inﬁltrate the CNS parenchyma in high num-
bers. This is opposite for B cells and even more so for plasma cells.
Those cells tend to accumulate predominantly in the connective
tissue spaces of the brain, such as the perivascular spaces and the
meninges. Furthermore, plasma cells accumulate later in the CNS
in relation to disease stage and persist within the brain even at
time points, when T-cell and B-cell inﬂammation is cleared. This
may be explained by the existence of a population of long-lived
plasma cells, which may accumulate in the CNS in chronic
inﬂammatory conditions. It may also explain the persistence of
oligoclonal bands in the CSF in chronic brain inﬂammation,
which may be seen for a prolonged time after recovery (Meinl
et al., 2006).
Regarding neurodegeneration, our study focused on markers for
the disturbances of fast axonal transport and the formation of
axonal swellings and end-bulbs. Disturbance of fast axonal trans-
port is currently the most accurate and sensitive marker for acute
axonal injury, occurring at a short-time window before axonal
death, whereas axonal swellings and end-bulbs may persist at
sites of damage for an extended period (Li et al., 1995). Thus,
the disturbance of fast axonal transport seems to be a suitable
marker to identify the acute or progressive damage, which takes
place at the time of axonal death. The detection of dying neuronal
cell bodies is much more difﬁcult. Neuronal loss has previously
been shown to occur in active cortical and deep grey matter
lesions (Peterson et al., 2001; Cifelli et al., 2002; Wegner et al.,
2006). In some cases with active cortical lesions, associated with
profound meningeal inﬂammation, neuronal apoptosis has been
observed (Peterson et al., 2001; Magliozzi et al., 2007).
However, in more slowly developing lesions, acute nerve cell
destruction is rare or absent, similar to what has been described
in the cortex of Alzheimer’s disease patients (Stadelmann et al.,
1998). Thus, neuronal loss in grey matter may contribute to
neurodegeneration in multiple sclerosis.
Understanding the relation between inﬂammation and neurode-
generation is of key importance for future therapeutic strategies
in multiple sclerosis. If inﬂammation drives subsequent neuro-
degeneration, proper anti-inﬂammatory therapies are the best
choice to stop the disease and to prevent further clinical deterio-
ration of the patients. If there is a neurodegenerative component,
which leads to brain damage independent from inﬂammation,
the effect of anti-inﬂammatory therapies will be limited and
neuroprotective strategies will become the prime target. Clinical
experience and magnetic resonance imaging studies suggest that
neurodegeneration may become independent from inﬂammation
in the progressive disease (Trapp and Nave, 2008). We show for
the ﬁrst time in a pathological study that axonal injury is invariably
associated with inﬂammation, especially in progressive multiple
sclerosis. Further, in late stages of the disease, inﬂammation
declines in a considerable proportion of the patients to an
extent, which is similar to that seen in age-matched controls.
This indicates that the inﬂammatory reaction may die out at late
stages of the disease. If there is a neurodegenerative component,
which progresses independently from inﬂammation, one would
predict that in such patients axonal injury continues. This was
not the case in our study. In contrast, axonal injury in such
patients was similar in extent, compared with age-matched
controls.
This, however, does not mean that there is no further brain
damage in multiple sclerosis patients, when the inﬂammatory
process has stopped. In such patients acute axonal injury does
not return to zero, but rather to the levels seen in age-matched
controls. Furthermore, confounding pathology is frequently seen in
aged multiple sclerosis patients. We have previously shown that
Alzheimer’s disease lesions develop in multiple sclerosis patients at
similar rates compared with those present in a normal aging cohort
(Dal-Bianco et al., 2008). In our present study, we could also
show that in patients with concomitant multiple sclerosis and
Inﬂammation and neurodegeneration in multiple sclerosis Brain 2009: 132; 1175–1189 | 1187Alzheimer’s disease, acute axonal injury is more pronounced
compared to that in non-Alzheimer’s multiple sclerosis patients.
The same holds true for patients with concomitant vascular
lesions. Thus, in patients with profound multiple sclerosis related
brain damage, which exceeds the functional reserve capacity of
the nervous tissue, such age related or concomitant brain damage
may give rise to further progression of functional deﬁcits, even
when the multiple sclerosis related disease process has stopped.
Supplementary material
Supplementary material is available at Brain online.
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